APNmAb005 vs Bepranemab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline

APNmAb005

Developed by APRINOIA Therapeutics

Phase 1 in Alzheimer's Diseasemonoclonal antibody
Weak signal

NCT05344989 · Phase 1 · status unknown

This is a randomized, placebo-controlled study with full blinding of participants, care providers, and assessors, though it is an early, safety-focused, first-in-human study in healthy volunteers rather than a disease-population efficacy trial, with small dose-cohort sizes. Results have not yet been posted.

No aligned efficacy figure on record for this race.

Bepranemab

Developed by UCB

Phase 2 in Alzheimer's Diseasemonoclonal antibody
Partial signal

NCT04867616 · Phase 2 · completed

This randomized, quadruple-blind, placebo-controlled Phase 2a trial (TOGETHER) assigned 466 people with prodromal to mild Alzheimer's disease to two doses of bepranemab or placebo for 80 weeks. Its primary endpoint was the change in CDR-SB at Week 80. UCB reported that neither dose showed a benefit over placebo on this endpoint in the overall population, so the primary endpoint was missed. Some secondary measures and pre-defined subgroups favoured bepranemab, but these do not change the primary result. The result comes from the sponsor's press release.

Result from the sponsor's press release or a wire copy of it; no peer-reviewed publication or posted registry results were found.

Reported efficacy

Change from Baseline to Week 80 in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) total score (From from Baseline to Week 80): Primary endpoint, change in CDR-SB total score at Week 80: no benefit of low- or high-dose bepranemab over placebo in the overall study population (per UCB; no figures or p-value released). Key secondary outcomes favoured bepranemab: tau accumulation slowed by 33% to 58% and ADAS-Cog14 decline by 21% to 25% vs placebo. (missed)

Result source: NCT04867616

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAPNmAb005Bepranemab
CDR-SB, change—Not reported—Not reported
ADAS-Cog11, change—Not reported—Not reported
ADCS-ADL, change—Not reported—Not reported
MMSE, change—Not reported—Not reported
Amyloid PET, change (centiloids)—Not reported—Not reported

CDR-SB, change

APNmAb005
—Not reported
Bepranemab
—Not reported

ADAS-Cog11, change

APNmAb005
—Not reported
Bepranemab
—Not reported

ADCS-ADL, change

APNmAb005
—Not reported
Bepranemab
—Not reported

MMSE, change

APNmAb005
—Not reported
Bepranemab
—Not reported

Amyloid PET, change (centiloids)

APNmAb005
—Not reported
Bepranemab
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

APNmAb005: no structured comparison results are available for Alzheimer's Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Bepranemab
Primary endpoint, change in CDR-SB total score at Week 80: no benefit of low- or high-dose bepranemab over placebo in the overall study population (per UCB; no figures or p-value released). Key secondary outcomes favoured bepranemab: tau accumulation slowed by 33% to 58% and ADAS-Cog14 decline by 21% to 25% vs placebo. NCT04867616 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: APNmAb005's landscape · Bepranemab's landscape